Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Regenerative Medicine Market in the US to Grow at a CAGR of 23.5%, 2017-2021 with Acelity, Medtronic, MiMedx, Organogenesis & Zimmer Biomet Dominating - Research and Markets

Research and Markets
Posted on: 01 Aug 17

The "Regenerative Medicine Market in the US 2017-2021" report has been added to Research and Markets' offering.

The Regenerative Medicine Market in the US to grow at a CAGR of 23.53% during the period 2017-2021.

The report, Regenerative Medicine Market in the US 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

The latest trend gaining momentum in the market is the increasing strategic alliances. Major vendors are entering into strategic alliances with other vendors for drug development and manufacturing. The trend is anticipated during the forecast period. Leading vendors in the market are undertaking M&A to strengthen their global position and to improve their commercial capabilities. Through increasing strategic alliances, many companies are receiving upfront and royalty payment, which encourages many small companies to involve into R&D and develop novel regenerative medicine products.

According to the report, one of the major drivers for this market is CVD and diabetes in young adult and aging population. CVD is a common disease in the older population; however, it is growing high among young adults owing to lifestyle and over-indulgement in junk foods. A combined study conducted by the Department of Clinical and Experimental Medicine, University of Florence; Department of Health Sciences, University of Milano-Bicocca; and Department of Cardiology, S. Luca Hospital, IRCCS Istituto Auxologico Italiano, Italy in 2015, found that uncontrolled blood pressure increases the risk of CVDs such as stroke and heart attack.

Key vendors

  • Acelity
  • Medtronic
  • MiMedx
  • Organogenesis
  • Zimmer Biomet

Key Topics Covered:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

PART 05: Market landscape

PART 06: Pipeline portfolio

PART 07: Market segmentation by product

PART 08: Market segmentation by application

PART 09: Market segmentation by end-user

PART 10: Decision framework

PART 11: Drivers and challenges

PART 12: Market trends

PART 13: Vendor landscape

PART 14: Key vendor analysis

For more information about this report visit

View source version on

Business Wire

Last updated on: 01/08/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.